{"id":"uninterrupted-apixaban","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Bleeding"},{"rate":"0.5-1%","effect":"Gastrointestinal bleeding"},{"rate":"1-2%","effect":"Nausea"},{"rate":"0.5-1%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Apixaban selectively inhibits Factor Xa, a serine protease essential for both the intrinsic and extrinsic pathways of blood coagulation. By blocking Factor Xa, it prevents the generation of thrombin and subsequent fibrin clot formation. The term 'uninterrupted' refers to a dosing strategy maintaining continuous anticoagulation without gaps.","oneSentence":"Apixaban is a Factor Xa inhibitor that prevents blood clot formation by blocking a key enzyme in the coagulation cascade.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:19.701Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT05292846","phase":"PHASE4","title":"Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures","status":"UNKNOWN","sponsor":"Hospital Universitario La Fe","startDate":"2022-01-20","conditions":"Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction","enrollment":200},{"nctId":"NCT02608099","phase":"PHASE4","title":"Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation","status":"COMPLETED","sponsor":"Baim Institute for Clinical Research","startDate":"2015-11","conditions":"Atrial Fibrillation","enrollment":300},{"nctId":"NCT02120560","phase":"PHASE4","title":"Anticoagulation in AF Ablation and Effects on Neurocognitive Function","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2014-07","conditions":"Atrial Fibrillation, Cerebrothromboembolus, Neurocognitive Function","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Uninterrupted Eliquis"],"phase":"marketed","status":"active","brandName":"Uninterrupted apixaban","genericName":"Uninterrupted apixaban","companyName":"Baim Institute for Clinical Research","companyId":"baim-institute-for-clinical-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apixaban is a small molecule inhibitor of coagulation factor X, classified as an INHIBITOR. It is used as a direct-acting oral anticoagulant for conditions such as coronary artery disease, atrial fibrillation, and bleeding, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}